3 days Ago By ABMN Staff
Zions Bancorporation N.A. decreased its stake in Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX – Free Report ) by 27.
8% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 216 shares of the pharmaceutical company’s stock after selling 83 shares during the quarter. Zions Bancorporation N.
A.’s holdings in Vertex Pharmaceuticals were worth $101,000 as of its most recent filing with the Securities and Exchange Commission. Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company.
GHP Investment Advisors Inc. acquired a new position in shares of Vertex Pharmaceuticals in the 2nd quarter valued at $29,000. Meeder Advisory Services Inc.
grew its stake in Vertex Pharmaceuticals by 39.4% in the second quarter. Meeder Advisory Services Inc.
now owns 5,572 shares of the pharmaceutical company’s stock valued at $2,612,000 after acquiring an additional 1,574 shares during the period. DekaBank Deutsche Girozentrale increased its holdings in shares of Vertex Pharmaceuticals by 2.1% in the second quarter.
DekaBank Deutsche Girozentrale now owns 501,509 shares of the pharmaceutical company’s stock worth $237,126,000 after acquiring an additional 10,380 shares in the last quarter. Oppenheimer & Co. Inc.
raised its position in shares of Vertex Pharmaceuticals by 8.7% during the second quarter. Oppenheimer & Co.
Inc. now owns 13,729 shares of the pharmaceutical company’s stock worth $6,435,000 after purchasing an additional 1,099 shares during the period. Finally, Nicholas Investment Partners LP lifted its holdings in shares of Vertex Pharmaceuticals by 29.
8% during the 2nd quarter. Nicholas Investment Partners LP now owns 5,636 shares of the pharmaceutical company’s stock valued at $2,642,000 after purchasing an additional 1,293 shares in the last quarter. Institutional investors own 90.
96% of the company’s stock. Vertex Pharmaceuticals Stock Performance VRTX opened at $485.37 on Monday.
The company has a quick ratio of 2.26, a current ratio of 2.52 and a debt-to-equity ratio of 0.
02. The stock has a market cap of $125.25 billion, a price-to-earnings ratio of 31.
50 and a beta of 0.40. Vertex Pharmaceuticals Incorporated has a 12-month low of $341.
85 and a 12-month high of $510.64. The business has a 50 day moving average of $483.
72 and a 200-day moving average of $450.41. Wall Street Analyst Weigh In A number of research firms recently issued reports on VRTX.
Needham & Company LLC reissued a “hold” rating on shares of Vertex Pharmaceuticals in a research note on Friday, July 26th. Barclays lowered shares of Vertex Pharmaceuticals from an “overweight” rating to an “equal weight” rating and raised their price objective for the stock from $472.00 to $509.
00 in a report on Monday, August 5th. Royal Bank of Canada reduced their target price on shares of Vertex Pharmaceuticals from $424.00 to $421.
00 and set a “sector perform” rating for the company in a research note on Tuesday, June 11th. Guggenheim lifted their price target on Vertex Pharmaceuticals from $450.00 to $558.
00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Finally, Truist Financial reaffirmed a “buy” rating and set a $550.00 price objective (up from $508.
00) on shares of Vertex Pharmaceuticals in a research report on Monday, August 5th. Three analysts have rated the stock with a sell rating, eight have issued a hold rating and sixteen have given a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $485.
91. Read Our Latest Stock Analysis on VRTX Insider Activity at Vertex Pharmaceuticals In other news, CMO Carmen Bozic sold 2,280 shares of the business’s stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $471.
72, for a total transaction of $1,075,521.60. Following the completion of the sale, the chief marketing officer now owns 30,099 shares in the company, valued at $14,198,300.
28. The sale was disclosed in a filing with the SEC, which is available at this hyperlink . In other Vertex Pharmaceuticals news, Director Bruce I.
Sachs sold 5,295 shares of Vertex Pharmaceuticals stock in a transaction dated Thursday, August 1st. The shares were sold at an average price of $508.00, for a total value of $2,689,860.
00. Following the completion of the sale, the director now owns 40,000 shares in the company, valued at approximately $20,320,000. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website .
Also, CMO Carmen Bozic sold 2,280 shares of the stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $471.72, for a total transaction of $1,075,521.
60. Following the transaction, the chief marketing officer now owns 30,099 shares in the company, valued at approximately $14,198,300.28.
The disclosure for this sale can be found here . In the last 90 days, insiders have sold 34,047 shares of company stock worth $16,843,806. Insiders own 0.
20% of the company’s stock. About Vertex Pharmaceuticals ( Free Report ) Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.
See Also Want to see what other hedge funds are holding VRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vertex Pharmaceuticals Incorporated ( NASDAQ:VRTX – Free Report ). Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.
com's FREE daily email newsletter ..
